Search Results - hugh+smyth

14 Results Sort By:
Dual-action topical formulations for enhanced skin penetration and targeted dermal repair
Background Dermatological and cosmetic treatments increasingly focus on targeted delivery of active compounds to the deeper skin layers to combat photoaging, oxidative damage, and carcino­genesis. However, the stratum corneum presents a formidable barrier to percutaneous absorption, limiting the efficacy of topically applied actives. Conventional...
Published: 8/14/2025   |   Inventor(s): Hugh Smyth, Patricia Martins
Keywords(s):  
Category(s): Life sciences > Therapeutics > Formulation, Life sciences > Therapeutics > Drug delivery
High-dose dry powder inhaler for dual pulmonary and oral indomethacin delivery
Background Dry powder inhalers (DPIs) offer a non-invasive and rapid route for drug delivery, particularly for medications requiring swift systemic action. This is especially relevant for poorly soluble drugs such as indomethacin, where oral admini­stration is often limited by gastrointestinal degradation and adverse side effects. For indications...
Published: 8/14/2025   |   Inventor(s): Hugh Smyth, Jamie Spahn, Feng Zhang
Keywords(s):  
Category(s): Life sciences > Therapeutics > Formulation, Life sciences > Therapeutics > Drug delivery
Inhalable vancomycin–DNase powder for eradication of MRSA lung infections
Background Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of hospital-acquired pneumonia, contributing to elevated mortality, prolonged hospitalizations, and increased healthcare costs. The persistence of MRSA in the lungs is largely due to its ability to form biofilms and generate persister cells, both of which protect the bacteria...
Published: 8/14/2025   |   Inventor(s): Hugh Smyth, Rex Moore
Keywords(s):  
Category(s): Life sciences > Therapeutics > Formulation
Optimized inhalation formulation of clofazimine and amikacin for targeted treatment of respiratory infections
The invention describes a pharmaceutical composition combining clofazimine and amikacin for inhalation to treat respiratory diseases like tuberculosis. This formulation enhances drug delivery to the lungs, improving efficacy and reducing systemic side effects. Background Bacterial infections, particularly those caused by mycobacteria such as Mycobacterium...
Published: 10/15/2024   |   Inventor(s): Hugh Smyth, Ashlee Brunaugh
Keywords(s):  
Category(s): Life sciences > Therapeutics > Manufacturing platform
Advanced nanoparticle delivery system for targeted pulmonary administration of therapeutic nucleic acids
Lipid nanoparticles (LNPs) are designed for delivering RNA to lung tissues via inhalation. Composed of ionizable lipids, phospholipids, PEG-lipids, and cholesterol, they encapsulate RNA for therapeutic or immunological purposes, maintaining stability during nebulization. Background Gene therapy and editing hold significant promise for treating genetic...
Published: 10/15/2024   |   Inventor(s): Hugh Smyth, Hairui Zhang, Robert Williams
Keywords(s):  
Category(s): Life sciences > Therapeutics > Formulation, Life sciences > Therapeutics > Drug delivery
Individualized intranasal delivery system for direct pharmaceutical administration to the brain
The technology involves a customizable nasal delivery device for precise administration of medications directly to the brain, bypassing traditional barriers. It uses imaging techniques for optimal placement, enhancing drug delivery efficiency and minimizing systemic side effects. Background Oral administration remains the predominant method for drug...
Published: 10/11/2024   |   Inventor(s): Hugh Smyth, Robert Williams, Zachary Warnken, Yang Lu
Keywords(s):  
Category(s): Life sciences > Therapeutics > Drug delivery, Life sciences > Medical technology > Medical devices
Pegylated aminoglycoside compounds for enhanced treatment of biofilm infections
Pegylated aminoglycoside compounds, like m-PEG-tobramycin, combine antibiotics with polyethylene glycol to enhance solubility, stability, and bioavailability, effectively penetrating and disrupting biofilm infections resistant to standard treatments. Background Biofilm-associated infections present a significant challenge in medical and industrial...
Published: 7/2/2025   |   Inventor(s): Hugh Smyth, Ju Du
Keywords(s):  
Category(s): Life sciences > Therapeutics > Small molecule, Life sciences > Agriculture > Animal/veterinary
Inhaled formulations of the NSAID indomethacin
Background Patients suffering from headache and migraine have a limited list of thera­peutic options that often is shortened by issues stemming from tolerability or efficacy. For this reason, there is a big push in the industry to develop inhaled treatments for these disorders. The invention described here repurposes a compound with known efficacy...
Published: 5/8/2024   |   Inventor(s): Hugh Smyth, Feng Zhang, Jamie Spahn
Keywords(s):  
Category(s): Life sciences > Therapeutics > Drug delivery, Life sciences > Therapeutics > Manufacturing platform
Advancements in pulmonary antibiotic delivery: innovations for multidrug-resistant infections
Background Antibiotics like Tigecycline are vital for combating bacterial infections, but their intravenous delivery restricts usage to healthcare facilities, limiting options for patients outside such settings. The rise of multidrug-resistant respiratory infections, like those caused by S. maltophilia, necessitates innovative delivery approaches....
Published: 5/8/2024   |   Inventor(s): Hugh Smyth, Varsha Nair
Keywords(s):  
Category(s): Life sciences > Therapeutics > Drug delivery
Real-time breath adaptive nebulizer for optimal pulmonary drug delivery
Problem Nebulizers produce an inhalable mist for localized drug delivery and are used to treat lung diseases including COPD and cystic fibrosis. The mist produced by the nebulizer is composed of droplets of a defined size, and droplet size and velocity dictate the efficiency of nebulized drug delivery. Currently available commercial nebulizers utilize...
Published: 8/23/2024   |   Inventor(s): Hugh Smyth, Matthew Herpin
Keywords(s):  
Category(s): Life sciences > Therapeutics > Drug delivery
1 2